428 related articles for article (PubMed ID: 28679436)
21. Diabetic dyslipidemia and atherosclerosis.
Shepherd J
Schweiz Med Wochenschr; 1994 Nov; 124(44):1933-7. PubMed ID: 7973520
[TBL] [Abstract][Full Text] [Related]
22. Changes in plasma lipid and lipoprotein levels in men and women after a program of moderate exercise.
Brownell KD; Bachorik PS; Ayerle RS
Circulation; 1982 Mar; 65(3):477-84. PubMed ID: 7055869
[TBL] [Abstract][Full Text] [Related]
23. Niacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterol.
Chrysant SG; Ibrahim M
J Clin Hypertens (Greenwich); 2006 Jul; 8(7):493-9; quiz 500-1. PubMed ID: 16849903
[TBL] [Abstract][Full Text] [Related]
24. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).
May HT; Anderson JL; Pearson RR; Jensen JR; Horne BD; Lavasani F; Yannicelli HD; Muhlestein JB
Am J Cardiol; 2008 Feb; 101(4):486-9. PubMed ID: 18312763
[TBL] [Abstract][Full Text] [Related]
25. Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease.
Miller M; Ginsberg HN; Schaefer EJ
Am J Cardiol; 2008 Apr; 101(7):1003-8. PubMed ID: 18359322
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of a telephone-based medical nutrition program on blood lipid and lipoprotein metabolism: Results of Our Healthy Heart.
Miller KE; Martz DC; Stoner C; Jowers A; Taheri ML; Sarzynski MA; Davis RAH; Plaisance EP
Nutr Diet; 2018 Feb; 75(1):73-78. PubMed ID: 29411495
[TBL] [Abstract][Full Text] [Related]
27. Elevated postprandial triglyceride-rich lipoproteins in patients with diabetes and stable coronary artery disease correlated with early renal damage and systemic inflammation.
Guo X; Zhai Y; Song C; Mi Z; Peng J; Guo J; Teng X; Zhang D
Lipids Health Dis; 2023 May; 22(1):58. PubMed ID: 37138333
[TBL] [Abstract][Full Text] [Related]
28. Serumlipoprotein cholesterol in sedentary and trained male patients with coronary heart disease.
Berg A; Keul J; Ringwald G; Stippig J; Deus B
Clin Cardiol; 1981; 4(5):233-7. PubMed ID: 7307359
[TBL] [Abstract][Full Text] [Related]
29. Angiopoietin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia.
Chen PY; Gao WY; Liou JW; Lin CY; Wu MJ; Yen JH
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298929
[TBL] [Abstract][Full Text] [Related]
30. The effects of estradiol on blood lipids and lipoproteins in postmenopausal women.
Fåhraeus L
Obstet Gynecol; 1988 Nov; 72(5 Suppl):18S-22S. PubMed ID: 3173937
[TBL] [Abstract][Full Text] [Related]
31. Lipids, lipoproteins, and exercise.
Durstine JL; Grandjean PW; Cox CA; Thompson PD
J Cardiopulm Rehabil; 2002; 22(6):385-98. PubMed ID: 12464825
[TBL] [Abstract][Full Text] [Related]
32. Dyslipidemias and Cardiovascular Prevention: Tailoring Treatment According to Lipid Phenotype.
Sanin V; Pfetsch V; Koenig W
Curr Cardiol Rep; 2017 Jul; 19(7):61. PubMed ID: 28528455
[TBL] [Abstract][Full Text] [Related]
33. Aerobic exercise, lipoproteins, and cardiovascular disease: benefits and possible risks.
Herzberg GR
Can J Appl Physiol; 2004 Dec; 29(6):800-7. PubMed ID: 15630151
[TBL] [Abstract][Full Text] [Related]
34. Apolipoprotein E phenotypes, serum lipoproteins and apolipoproteins in angiographically assessed coronary heart disease.
Stuyt PM; Brenninkmeijer BJ; Demacker PN; Hendriks JC; van Elteren P; Stalenhoef AF; van 't Laar A
Scand J Clin Lab Invest; 1991 Sep; 51(5):425-35. PubMed ID: 1947727
[TBL] [Abstract][Full Text] [Related]
35. Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease.
Cohen DE; Fisher EA
Semin Liver Dis; 2013 Nov; 33(4):380-8. PubMed ID: 24222095
[TBL] [Abstract][Full Text] [Related]
36. Lipoprotein electrophoretic patterns, serum lipids, and coronary heart disease.
Masarei JR; Summers M; Curnow DH; Cullen KJ; McCall MG; Stenhouse NS; Welborn TA
Br Med J; 1971 Jan; 1(5740):78-82. PubMed ID: 5539180
[TBL] [Abstract][Full Text] [Related]
37. Beverage Consumption and Longitudinal Changes in Lipoprotein Concentrations and Incident Dyslipidemia in US Adults: The Framingham Heart Study.
Haslam DE; Peloso GM; Herman MA; Dupuis J; Lichtenstein AH; Smith CE; McKeown NM
J Am Heart Assoc; 2020 Mar; 9(5):e014083. PubMed ID: 32098600
[TBL] [Abstract][Full Text] [Related]
38. Low-density lipoprotein cholesterol target attainment in patients with stable or acute coronary heart disease in the Asia-Pacific region: results from the Dyslipidemia International Study II.
Poh KK; Ambegaonkar B; Baxter CA; Brudi P; Buddhari W; Chiang FT; Horack M; Jang Y; Johnson B; Lautsch D; Sawhney J; Vyas A; Yan BP; Gitt AK
Eur J Prev Cardiol; 2018 Dec; 25(18):1950-1963. PubMed ID: 30198749
[TBL] [Abstract][Full Text] [Related]
39. Mendelian randomization to assess causal effects of blood lipids on coronary heart disease: lessons from the past and applications to the future.
Burgess S; Harshfield E
Curr Opin Endocrinol Diabetes Obes; 2016 Apr; 23(2):124-30. PubMed ID: 26910273
[TBL] [Abstract][Full Text] [Related]
40. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
Ooi EM; Watts GF; Sprecher DL; Chan DC; Barrett PH
J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
